Skip to main content

MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

06 Jul 2026 Evaluate
Glenmark Pharmaceuticals has informed about the launch of Olanzapine for Injection, 10 mg/vial, Single?Dose Vial. Glenmark’s Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa® IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1761.45
Dr. Reddys Labs. 1313.00
Cipla 1344.00
Lupin 1943.20
Zydus Lifesciences 1166.55
View more..